Amgen Inc.

Isis Pharmaceuticals, Inc.

Other

Murielle M Veniant-Ellison

Zhulun Wang

Xiaoshan Min

Kenneth William Walker

Gunasekaran Kannan

Agnes Eva Hamburger

Jackie Zeqi Sheng

Yi Lin Zhang

Jie Tang

YuMei Xiong

Grant Shimamoto

Junming Yie

David J Lloyd

Ian Nevin Foltz

Bryan D Lemon

Neeraj Jagdish Agrawal

Darren L Bates

Donghui Shi

Christopher Murawsky

Jinghong Wang

Brandon C P Clavette

Shu-yin Ho

Glenn N Sivits, Jr

Renee Komorowski

Kenneth W Dobie

Sanjay Bhanot

Leslie Phillip Miranda

Jerry Ryan Holder

Richard A Lindberg

Shu-Chen Lu

Marissa Mock

Shanaka Stanislaus

John R Shutter

Robert McKay

Bin Wu

Yuan Cheng

Jing M Xu

James Richard Falsey

Kelvin C Sham

Bradley J Herberich

Colin Victor Gegg, Jr

Sanjay K Pandey

Yi Zhang

Chawita Netirojjanakul

Jing Xu

Katherine Ann Winters

Kelvin Sham

Yumei Xiong

Method of treating metabolic diseases and disorders using a composition comprising a GLP-V/GIPR antigen binding protein fusion protein are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises the C-terminus of a GLP-1 analog fused to the N-terminus of the light chain variable or heavy chain variable region of an antibody or functional fragment thereof that binds GIPR, optionally with a linker in between.

Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (GIPR)/GLP-1 receptor agonist fusion proteins

Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

Nucleic acid molecules encoding binding proteins for gastric inhibitory peptide receptor (GIPR)

GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

Growth differentiation factor 15 (GDF-15) polypeptides

Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists

Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

Method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR)

Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

Growth differentiation factor 15 (GDF-15) constructs

GLP-1 compounds comprising GLP-1 analogs and methods of using the GLP-1 compounds for treating metabolic disorders, enhancing insulin expression, and promoting insulin secretion in a patient are provided.

GLP-1 compounds

Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.

Modulation of forkhead box O1A expression

Growing community of inventors

Thousand Oaks, CA, United States of America

Murielle M Veniant-Ellison